Centocor ASPIRE T29 Study
- Date:
- 1999-2004
- Reference:
- SA/KET/A/1/10
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Comprises papers relating to the T29 study "A randomised double-blind trial of anti-TNFalpha chimeric monoclonal antibody (Infliximab) in combination with methotrexate alone for the treatment of patient with early rheumatoid arthritis."
The purpose of the study was to determine whether Infliximab at two different does in combination with methotrexate compared with the treatment of methotrexate alone reduces the signs and symptoms of early rheumatoid arthritis and whether the doses of infliximab and methotrexate can slow down or stop joint damage. The study involved 1050 patients participating for one year with a six month follow up and an annual follow up for five years. The Principal investigator of the study was Ravinder Maini on behalf of the Kennedy Institute and the sponsor of the study was Centocor.
See SA/KET/A/2 for further Centocor research collaboration papers.